In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniae-Reference-Cited by-同舟云学术

In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniae

Published:2004-05 Issue:1 Volume:49 Page:41-46
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Burgess David S,Hall Ronald G

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference29 articles.

1. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactmases;Bedenic;Clin Microbiol Infect,2001

2. Extended-spectrum β-lactamases in the 21st century;Bradford;Clin Microbiol Rev,2001

3. Clinical and microbiological analysis of a hospital's extended spectrum beta-lactamase producing isolates over a 2 year period;Burgess;Pharmacotherapy,2003

4. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam by continuous infusion and intermittent dosing;Burgess;Clin Ther,2002

5. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion;Burgess;Clin Ther,2000

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections;Clinical Infectious Diseases;2023-07-18

2. Fluorescence Microscopy: Determination of Meropenem Activity against Klebsiella pneumoniae;Antibiotics;2023-07-10

3. Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniae;International Journal of Antimicrobial Agents;2023-05

4. Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI);JAC-Antimicrobial Resistance;2023-03-02

5. High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production;Open Forum Infectious Diseases;2023-01-25